Retrieve available abstracts of 161 articles: HTML format
Single Articles
June 2025
WANG L, Zhao Y, Duan B, Wang Y, et al Iron Quantification Using Spectral CT-Based Material Decomposition Technique for
Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031. PubMedAbstract available
GUO X, Wu L, Lai J, Wu Y, et al Causal Associations Between Lipids, NPC1L1, and Liver Cancer Risk: Insights From
Mendelian Randomization and Bioinformatics.
J Gastroenterol Hepatol. 2025;40:1602-1615. PubMedAbstract available
XIA Y, Tie J, Wang G, Wu H, et al Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or
Refractory ascites: A Multicenter Cohort Study.
J Gastroenterol Hepatol. 2025;40:1574-1585. PubMedAbstract available
May 2025
NIIZEKI T, Mawatari S, Shibata M, Sasaki R, et al Comparison Analysis of Lenvatinib Plus Transcatheter Arterial Chemoembolization
Versus Atezolizumab Plus Bevacizumab as First-Line Therapy for Intermediate-Stage
Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria.
J Gastroenterol Hepatol. 2025 May 31. doi: 10.1111/jgh.17024. PubMedAbstract available
MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients
With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002. PubMedAbstract available
JOSHI A, Raja HAA, Roy P, Latif F, et al Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure
Gradient in Liver Cirrhosis: A Meta-Analysis.
J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999. PubMedAbstract available
QIN J, Zhu W, Zhou W Navigating the Paradox of IL-22: Friend or Foe in Hepatic Health?
J Gastroenterol Hepatol. 2025 May 13. doi: 10.1111/jgh.16991. PubMedAbstract available
LIOU WL, Tan SY, Yamada H, Krishnamoorthy T, et al Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular
Carcinoma Surveillance: A Prospective Cohort Study.
J Gastroenterol Hepatol. 2025 May 10. doi: 10.1111/jgh.16997. PubMedAbstract available
DONG L, Zhang H, Kang Y, Wang F, et al NLRP3 and Gut-Liver Axis: New Possibility for the Treatment of Alcohol-Associated
Liver Disease.
J Gastroenterol Hepatol. 2025;40:1070-1078. PubMedAbstract available
FUKAMIZO K, Hagiwara Y, Kimura T, Matsuyama Y, et al Individualized Effects of Weight Gain in Adulthood on the Development of MASLD in
Japanese Non-Obese Individuals.
J Gastroenterol Hepatol. 2025;40:1255-1262. PubMedAbstract available
CHANG YW, Kuo CN, Chang CL, Hsu JC, et al Sequential Treatment of Metastatic Colorectal Cancer in Taiwan: Real-World
Evidence From Regorafenib and Trifluridine/Tipiracil Use.
J Gastroenterol Hepatol. 2025;40:1135-1142. PubMedAbstract available
April 2025
TAMAKI N, Huang DQ, Lee HW, Park SY, et al Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus
Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986. PubMedAbstract available
LEE HA, Lee HW, Seo YS, Sinn DH, et al Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg
Seroclearance.
J Gastroenterol Hepatol. 2025 Apr 24. doi: 10.1111/jgh.16973. PubMedAbstract available
Correction to "PLK2 Inhibited Oxidative Stress and Ameliorated Hepatic
Ischemia-Reperfusion Injury Through Phosphorylating GSK3beta".
J Gastroenterol Hepatol. 2025 Apr 10. doi: 10.1111/jgh.16966. PubMed
FILHO VOC, Passos PRC PCED1A as a Predictive Biomarker for Immunotherapy and Anti-Angiogenic Treatment
in Hepatocellular and Colorectal Cancer.
J Gastroenterol Hepatol. 2025 Apr 9. doi: 10.1111/jgh.16969. PubMed
LI J, Zhao Y, Wang Z, Ma A, et al Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR
Pathway in Hepatic Steatosis.
J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16950. PubMedAbstract available
PARK SH, Song SJ, Lee JA, Shin JA, et al Effects of Aging on the Severity of Liver Injury in Mice With Iron Overload.
J Gastroenterol Hepatol. 2025;40:1016-1025. PubMedAbstract available
MATONO T, Tada T, Kumada T, Hiraoka A, et al Survival Outcomes Associated With Radiological Progressive Disease Subtypes in
Patients With Atezolizumab and Bevacizumab-Treated HCC.
J Gastroenterol Hepatol. 2025;40:949-959. PubMedAbstract available
ZHAO N, Wang H, Zhang M, Tian W, et al Characterization of NK Cells Using Single-Cell RNA Sequencing in Patients With
Acute-On-Chronic Liver Failure.
J Gastroenterol Hepatol. 2025;40:917-929. PubMedAbstract available
ZHAI X, He X, Huang A, Liu Z, et al Analysis of Immunometabolic Profiles in Patients With Chronic Drug-Induced Liver
Injury and Validation in Mice to Reveal Potential Mechanisms.
J Gastroenterol Hepatol. 2025;40:987-1003. PubMedAbstract available
March 2025
Correction to 'Cirrhosis in primary practice: many patients remain potentially
undiagnosed and are not receiving liver cancer surveillance'.
J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918. PubMed
TAO Q, Zhou Y, Chen G, Sun J, et al Cisplatin Promotes Hepatotoxicity by cGAS-STING Mediated Innate Immune Response.
J Gastroenterol Hepatol. 2025 Mar 7. doi: 10.1111/jgh.16926. PubMedAbstract available
JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and
Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914. PubMedAbstract available
February 2025
GIRI S, Ingawale S, Khatana G, Gore P, et al Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in
the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922. PubMedAbstract available
LIAO C, Zhang Y, Yang J, Wang S, et al Single-Cell Transcriptomic Analysis Reveals an Aggressive Basal-Like Tumor Cell
Subpopulation Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma.
J Gastroenterol Hepatol. 2025 Feb 24. doi: 10.1111/jgh.16915. PubMedAbstract available
EZHILARASAN D Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom.
J Gastroenterol Hepatol. 2025;40:367-378. PubMedAbstract available
SINGH SP, Bhatia V, Kale P, Kumar G, et al Bowel Colonization With Carbapenem-Resistant Bacteria Is Associated With
Short-Term Outcomes in Patients With Acute-On-Chronic Liver Failure.
J Gastroenterol Hepatol. 2025;40:528-536. PubMedAbstract available
January 2025
ANG TL, Hang DV, Li JW, Ho JCL, et al APAGE Position Statements on Green and Sustainability in Gastroenterology,
Hepatology, and Gastrointestinal Endoscopy.
J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16896. PubMedAbstract available
PENG J, Zhang L, Dong Y, Long W, et al Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A
Retrospective Cohort Study Over 5 Years.
J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889. PubMedAbstract available
SONG BG, Park G, Goh MJ, Kang W, et al A Risk Prediction Model for Hepatocellular Carcinoma in the General Population
Without Traditional Risk Factors for Liver Disease.
J Gastroenterol Hepatol. 2025 Jan 29. doi: 10.1111/jgh.16893. PubMedAbstract available
SHIN SK, Mishima Y, Lee Y, Kwon OS, et al Current Landscape of Adoptive Cell Therapy and Challenge to Develop
"Off-The-Shelf" Therapy for Hepatocellular Carcinoma.
J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16872. PubMedAbstract available
WANG M, Zhang Q, Wang J Expression of PCED1A in Hepatocellular Carcinoma and Colorectal Cancer and Its
Relationship with Immune Infiltration: Potential as a Diagnostic Marker.
J Gastroenterol Hepatol. 2025 Jan 26. doi: 10.1111/jgh.16890. PubMedAbstract available
REN X, Wu Y, Song T, Yang Q, et al Clonorchis sinensis Promotes Intrahepatic Cholangiocarcinoma Progression by
Activating FASN-Mediated Fatty Acid Metabolism.
J Gastroenterol Hepatol. 2025 Jan 13. doi: 10.1111/jgh.16879. PubMedAbstract available
ZHAO Y, Zhu W, Dong S, Zhang H, et al Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of
Pancreatic and Hepatobiliary Cancers.
J Gastroenterol Hepatol. 2025 Jan 8. doi: 10.1111/jgh.16873. PubMedAbstract available
HATANAKA T, Kakizaki S, Hiraoka A, Tada T, et al Reliable Performance of mALBI Grade-Based Risk Models for Predicting the
Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus
Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
J Gastroenterol Hepatol. 2025 Jan 6. doi: 10.1111/jgh.16871. PubMedAbstract available
KIM A, Kang D, Choi SC, Sinn DH, et al Cardiometabolic risk factors and coronary atherosclerosis progression in patients
with metabolic dysfunction-associated steatotic liver disease: the influential
role of quantity over type.
J Gastroenterol Hepatol. 2025;40:258-264. PubMedAbstract available
GUPTA P, Hsu YC, Liang LL, Chu YC, et al Automatic localization and deep convolutional generative adversarial
network-based classification of focal liver lesions in computed tomography
images: A preliminary study.
J Gastroenterol Hepatol. 2025;40:166-176. PubMedAbstract available
TAMURA Y, Saeki C, Kanai T, Kiryu S, et al Comparison of the ability between dual-energy X-ray absorptiometry and
bioelectrical impedance analysis for diagnosing low skeletal muscle mass and
sarcopenia in patients with chronic liver disease.
J Gastroenterol Hepatol. 2025;40:274-281. PubMedAbstract available
VAZ K, Kemp W, Majeed A, Lubel J, et al Validation of serum non-invasive tests of liver fibrosis as prognostic markers of
clinical outcomes in people with fatty liver disease in Australia.
J Gastroenterol Hepatol. 2025;40:241-249. PubMedAbstract available
CUI XS, Li HZ, Li L, Xie CZ, et al Rodent model of metabolic dysfunction-associated fatty liver disease: a
systematic review.
J Gastroenterol Hepatol. 2025;40:48-66. PubMedAbstract available
December 2024
HU S, Kang H, Bae M, Kim MB, et al Histone Deacetylase 9 Deletion Inhibits Hepatic Steatosis and Adipose Tissue
Inflammation in Male Diet-Induced Obese Mice.
J Gastroenterol Hepatol. 2024 Dec 27. doi: 10.1111/jgh.16856. PubMedAbstract available
KOH HH, Kang M, Kim DG, Park JH, et al Comparative Validation of Prediction Models for HCC Outcomes in Living Donor
Liver Transplantation: Superiority of Tumor Markers to Imaging Study.
J Gastroenterol Hepatol. 2024 Dec 26. doi: 10.1111/jgh.16857. PubMedAbstract available
SALEEPOL A, Chulroek T, Vimonsuntirungsri T, Luangsukrerk T, et al Gastrointestinal: Direct Visualization of Biliary Tuberculosis.
J Gastroenterol Hepatol. 2024 Dec 11. doi: 10.1111/jgh.16836. PubMedAbstract available
CHEN J, Chen X, Cai H, Yang Y, et al The ubiquitination degradation of KLF15 mediated by WSB2 promotes lipogenesis and
progression of hepatocellular carcinoma via inhibiting PDLIM2 expression.
J Gastroenterol Hepatol. 2024 Dec 5. doi: 10.1111/jgh.16812. PubMedAbstract available
WONG DN, Hui RW, Mak LY, Seto WK, et al Gastrointestinal: Biliary Obstruction From Hepatic Artery Aneurysms: Implications
for Treatment Selection.
J Gastroenterol Hepatol. 2024 Dec 4. doi: 10.1111/jgh.16841. PubMed
NIKOLI A, Orfanidou M, Goulas A, Goulis DG, et al Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a
systematic review and meta-analysis.
J Gastroenterol Hepatol. 2024;39:2572-2581. PubMedAbstract available
MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and
meta-analysis of diagnostic test accuracy studies.
J Gastroenterol Hepatol. 2024;39:2582-2591. PubMedAbstract available
PAN L, Wang L, Ma H, Ding F, et al Relevance of combined influence of nutritional and inflammatory status on
non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of
lipid biomarkers.
J Gastroenterol Hepatol. 2024;39:2853-2862. PubMedAbstract available
US ALTAY D, Kaya Y, Mataraci Degirmenci D, Kocyigit E, et al Non-alcoholic fatty liver disease: The importance of physical activity and
nutrition education-A randomized controlled study.
J Gastroenterol Hepatol. 2024;39:2723-2734. PubMedAbstract available
TENG X, Shang J, Du L, Huang W, et al RNA-binding protein Trx regulates alternative splicing and promotes metastasis of
HCC via interacting with LINC00152.
J Gastroenterol Hepatol. 2024;39:2892-2902. PubMedAbstract available
KIM K, Lee Y, Lee JS, Kim MN, et al Incidence of metabolic dysfunction-associated steatotic liver disease and
advanced fibrosis and impact of overweight/obesity in elderly population: a
nationwide cohort study.
J Gastroenterol Hepatol. 2024;39:2845-2852. PubMedAbstract available
MORISHIMA S, Abe A, Okamoto S, Kapoor MP, et al Partially hydrolyzed guar gum suppresses binge alcohol-induced liver fat
accumulation via gut environment modulation in mice.
J Gastroenterol Hepatol. 2024;39:2700-2708. PubMedAbstract available
SUN F, Wang J, Ji X, Wang Z, et al CCL25 contributes to the pathogenesis of D-Gal/LPS-induced acute liver failure.
J Gastroenterol Hepatol. 2024;39:2880-2891. PubMedAbstract available
CHEE NM, Sinnanaidu RP, Chan WK Vitamin E improves serum markers and histology in adults with metabolic
dysfunction-associated steatotic liver disease: Systematic review and
meta-analysis.
J Gastroenterol Hepatol. 2024;39:2545-2554. PubMedAbstract available
LI Y, Dai C, Yang H, Zeng H, et al Cross-sectional and Mendelian randomization study of fibroblast growth factor 19
reveals causal associations with metabolic diseases.
J Gastroenterol Hepatol. 2024;39:2872-2879. PubMedAbstract available
November 2024
GE W, Wang Z, Zhong X, Chen Y, et al PLK2 inhibited oxidative stress and ameliorated hepatic ischemia-reperfusion
injury through phosphorylating GSK3beta.
J Gastroenterol Hepatol. 2024 Nov 19. doi: 10.1111/jgh.16815. PubMedAbstract available
JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al Clostridioides difficile infection increases in-hospital mortality, length of
stay, and hospital cost but not 30-day mortality in cirrhotic patients.
J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807. PubMedAbstract available
ZENG X, Liao Y, Cheng W Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by
inhibiting the activation and proliferation of hepatic stellate cells.
J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802. PubMedAbstract available
ABOONA MB, Danpanichkul P, Chen VL, Rangan P, et al Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol
intake.
J Gastroenterol Hepatol. 2024;39:2456-2463. PubMedAbstract available
LAM LK, Tan JT, Ooi PH, Zhang R, et al Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2
immunogenicity against the severe acute respiratory syndrome coronavirus 2
omicron variant.
J Gastroenterol Hepatol. 2024;39:2386-2393. PubMedAbstract available
WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus:
a systematic review and meta-analysis.
J Gastroenterol Hepatol. 2024;39:2299-2307. PubMedAbstract available
October 2024
ZHU W, Fan C, Liu B, Qin J, et al Therapeutic targets for hepatocellular carcinoma identified using proteomics and
Mendelian randomization.
J Gastroenterol Hepatol. 2024 Oct 30. doi: 10.1111/jgh.16785. PubMedAbstract available
PRINCE DS, Hoque S, Kim C, Maher S, et al Cirrhosis in primary practice: many patients remain potentially undiagnosed and
are not receiving liver cancer surveillance.
J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782. PubMedAbstract available
LI Y, Chen L, Li S, Song H, et al The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells
through facilitating TUBB4B mRNA stabilization.
J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765. PubMedAbstract available
ZHANG L, Xu L, Rong A, Cui Y, et al Effect of Rab18 on liver injury and lipid accumulation by regulating perilipin 2
and peroxisome proliferator-activated receptor gamma in non-alcoholic fatty liver
disease.
J Gastroenterol Hepatol. 2024;39:2219-2227. PubMedAbstract available
LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al LIVERSTAT for risk stratification for patients with metabolic
dysfunction-associated fatty liver disease.
J Gastroenterol Hepatol. 2024;39:2182-2189. PubMedAbstract available
YANG J, Choi WM, Lee D, Shim JH, et al Revisiting the steatosis-associated fibrosis estimator score in young Asian
subjects with steatotic liver disease and consideration for population
variability.
J Gastroenterol Hepatol. 2024;39:2112-2119. PubMedAbstract available
ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al Potential role of stem cells from human exfoliated deciduous teeth in inducing
liver regeneration.
J Gastroenterol Hepatol. 2024;39:2190-2196. PubMedAbstract available
September 2024
KU JL, Hsu JR, Li YT, Wu LL, et al Interplay among IL1R1, gut microbiota, and bile acids in metabolic
dysfunction-associated steatotic liver disease: a comprehensive review.
J Gastroenterol Hepatol. 2024 Sep 29. doi: 10.1111/jgh.16750. PubMedAbstract available
PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type
2 diabetes: a systematic review and meta-analysis.
J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752. PubMedAbstract available
HO CT, Tan EH, Lee PC, Su CW, et al Reply to "Association between proton-pump inhibitor use and recurrence of
hepatocellular carcinoma after hepatectomy: concerns to be addressed".
J Gastroenterol Hepatol. 2024 Sep 19. doi: 10.1111/jgh.16754. PubMed
EADIE L, Lo LA, Boivin M, Deol JK, et al Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.
J Gastroenterol Hepatol. 2024 Sep 3. doi: 10.1111/jgh.16730. PubMedAbstract available
NJEI B, Al-Ajlouni YA, Ameyaw P, Njei LP, et al Role of ammonia and glutamine in the pathogenesis and progression of metabolic
dysfunction-associated steatotic liver disease: A systematic review.
J Gastroenterol Hepatol. 2024;39:1788-1808. PubMedAbstract available
KIM D, Manikat R, Wijarnpreecha K, Cholankeril G, et al Estimated pulse wave velocity in metabolic dysfunction-associated steatotic liver
disease and all-cause/cause-specific mortality.
J Gastroenterol Hepatol. 2024;39:1950-1956. PubMedAbstract available
CHEN YT, Chen TI, Yin SC, Huang CW, et al Prevalence, proportions of elevated liver enzyme levels, and long-term
cardiometabolic mortality of patients with metabolic dysfunction-associated
steatotic liver disease.
J Gastroenterol Hepatol. 2024;39:1939-1949. PubMedAbstract available
August 2024
HENRY-BLAKE C, Balachandrakumar V, Kassab M, Devonport J, et al Lower hepatocellular carcinoma surveillance in metabolic dysfunction-associated
steatotic liver disease: Impact on treatment eligibility.
J Gastroenterol Hepatol. 2024 Aug 27. doi: 10.1111/jgh.16727. PubMedAbstract available
ZHANG X, Chen C, Wang Y, Xu J, et al Recurrence risk prediction models for hepatocellular carcinoma after liver
transplantation.
J Gastroenterol Hepatol. 2024 Aug 7. doi: 10.1111/jgh.16693. PubMedAbstract available
WU T, Ye J, Mo S, Ye M, et al Impact of nomenclature as metabolic associated steatotic liver disease on
steatotic liver disease prevalence and screening: a prospective population survey
in Asians.
J Gastroenterol Hepatol. 2024;39:1636-1647. PubMedAbstract available
BANERJEE A, Blinston D, Narain MA Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence
from a case of TNFAIP3 deficiency.
J Gastroenterol Hepatol. 2024;39:1706-1707. PubMed
FUKUNISHI Y, Hiraoka A, Tada F, Fukumoto M, et al Changes in characteristics of gastroenterology center inpatients in Japan because
of rapidly aging society.
J Gastroenterol Hepatol. 2024;39:1528-1534. PubMedAbstract available
July 2024
BIAN J, Sang X Association between proton-pump inhibitor use and recurrence of hepatocellular
carcinoma after hepatectomy: Concerns to be addressed.
J Gastroenterol Hepatol. 2024 Jul 25. doi: 10.1111/jgh.16694. PubMed
CHU CS, Chen HP, Lin PH, Cheng CC, et al Interleukin-1 receptor 1 deficiency worsens hepatocellular carcinoma, while
gemcitabine treatment alleviates the hepatocellular carcinoma-induced increase in
intra-hepatic immune cells.
J Gastroenterol Hepatol. 2024 Jul 15. doi: 10.1111/jgh.16674. PubMedAbstract available
XIN Z, Chen H, Xu J, Zhang H, et al Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion
in hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 Jul 7. doi: 10.1111/jgh.16677. PubMedAbstract available
NAKASHIMA R, Kitano Y, Okabe H, Tanizaki T, et al Rising pseudocysts in the hepatoduodenal ligament caused by a ruptured
intraductal papillary mucinous neoplasm with surgical treatment.
J Gastroenterol Hepatol. 2024 Jul 1. doi: 10.1111/jgh.16669. PubMed
MORI K, Akiyama Y, Tanaka M, Sato T, et al Deciphering metabolic dysfunction-associated steatotic liver disease: insights
from predictive modeling and clustering analysis.
J Gastroenterol Hepatol. 2024;39:1382-1393. PubMedAbstract available
MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers
in patients with nonalcoholic fatty liver disease: systematic review and network
meta-analysis.
J Gastroenterol Hepatol. 2024;39:1219-1229. PubMedAbstract available
LEE RC, Liang PC, Liang HL, Chen YF, et al Multicenter evaluation of the safety and efficacy of selective internal radiation
therapy with yttrium-90 resin microspheres in Taiwan: data from the RESIN
registry.
J Gastroenterol Hepatol. 2024;39:1318-1327. PubMedAbstract available
SUGITA H, Nakanuma S, Munesue S, Ishikawa T, et al Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal
obstruction syndrome.
J Gastroenterol Hepatol. 2024;39:1413-1421. PubMedAbstract available
June 2024
SUZUKI T, Matsuura K, Suzuki Y, Okumura F, et al Serum interleukin-6 levels at the start of the second course of atezolizumab plus
bevacizumab therapy predict therapeutic efficacy in patients with advanced
hepatocellular carcinoma: a multicenter analysis.
J Gastroenterol Hepatol. 2024 Jun 28. doi: 10.1111/jgh.16672. PubMedAbstract available
CHENG J, Yang S, Shou D, Chen J, et al FOXO1 induced fatty acid oxidation in hepatic cells by targeting ALDH1L2.
J Gastroenterol Hepatol. 2024 Jun 25. doi: 10.1111/jgh.16662. PubMedAbstract available
CHATZIPANAGIOTOU OP, Loukas C, Vailas M, Machairas N, et al Artificial intelligence in hepatocellular carcinoma diagnosis: a comprehensive
review of current literature.
J Gastroenterol Hepatol. 2024 Jun 23. doi: 10.1111/jgh.16663. PubMedAbstract available
MAUNG ST, Tanpowpong N, Satja M, Treeprasertsuk S, et al MRI for hepatocellular carcinoma and the role of abbreviated MRI for surveillance
of hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 Jun 20. doi: 10.1111/jgh.16643. PubMedAbstract available
MALIK S, Tenorio BG, Moond V, Dahiya DS, et al Systematic review of machine learning models in predicting the risk of
bleed/grade of esophageal varices in patients with liver cirrhosis: A
comprehensive methodological analysis.
J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645. PubMedAbstract available
HO CT, Fu CC, Tan EC, Kao WY, et al The association between proton-pump inhibitor use and recurrence of
hepatocellular carcinoma after hepatectomy.
J Gastroenterol Hepatol. 2024 Jun 12. doi: 10.1111/jgh.16640. PubMedAbstract available
WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic
liver and infected ascites.
J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637. PubMedAbstract available
LEE KJ, Moon JS, Lim JG, Huh H, et al PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease
in children.
J Gastroenterol Hepatol. 2024;39:1172-1182. PubMedAbstract available
May 2024
HAYASHI M, Abe K, Sugaya T, Takahata Y, et al A low baseline serum myostatin concentration is associated with poor clinical
outcome in patients with primary biliary cholangitis.
J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639. PubMedAbstract available
SUN Z, Guo Y, Xu X, Zhou C, et al Hydronidone induces apoptosis in activated hepatic stellate cells through
endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635. PubMedAbstract available
SHIN SK, Oh S, Chun SK, Ahn MJ, et al Immune signature and therapeutic approach of natural killer cell in chronic liver
disease and hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 May 27. doi: 10.1111/jgh.16584. PubMedAbstract available
LIU S, Gou H, Wei H, Chen S, et al Cholecystohepatic shunt pathway reduces secondary bile acid accumulation to
enhance natural killer T cell-mediated anti-hepatocellular carcinoma immunity.
J Gastroenterol Hepatol. 2024 May 15. doi: 10.1111/jgh.16548. PubMedAbstract available
KOUNTOURAS J, Zavos C, Vardaka E, Kyrailidi F, et al Helicobacter pylori and metabolic syndrome-related adipokines in nonalcoholic
fatty liver disease pathophysiology.
J Gastroenterol Hepatol. 2024 May 9. doi: 10.1111/jgh.16621. PubMed
LIM J, Kim JH, Kim SE, Han SK, et al Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using
prospective KACLiF cohort.
J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591. PubMedAbstract available
LEE J, Jin YJ, Shin SK, Kwon JH, et al Clinical outcomes of transarterial chemoembolization in Child-Turcotte Pugh class
A patients with a single small (=3 cm) hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 May 6. doi: 10.1111/jgh.16581. PubMedAbstract available
ENDO K, Kakisaka K, Abe T, Yusa K, et al Positive impact of obesity on the prognosis of liver cirrhosis.
J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590. PubMedAbstract available
LEE S, Choi J, Park JH, Lim CY, et al Dynamic liver volume change in predicting hepatic decompensation and long-term
effects of stereotactic body radiation therapy.
J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588. PubMedAbstract available
ZHONG W, Xu B, Lu Y, Chang J, et al Postoperative adjuvant chemotherapy is important for improving long-term survival
in patients with colorectal cancer liver metastases undergoing simultaneous
resection.
J Gastroenterol Hepatol. 2024;39:908-919. PubMedAbstract available
PEI X, Jiang W, Li L, Zeng Q, et al Mendelian-randomization study revealed causal relationship between nonalcoholic
fatty liver disease and osteoporosis/fractures.
J Gastroenterol Hepatol. 2024;39:847-857. PubMedAbstract available
MAKRI ES, Evripidou K, Polyzos SA Circulating leptin in patients with nonalcoholic fatty liver disease-related
liver fibrosis: a systematic review and a meta-analysis.
J Gastroenterol Hepatol. 2024;39:806-817. PubMedAbstract available
April 2024
QI S, Wei X, Zhao J, Wei X, et al Performance of MAST, FAST, and MEFIB in predicting metabolic
dysfunction-associated steatohepatitis.
J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16589. PubMedAbstract available
CAO QH, Liu H, Yan LJ, Wang HC, et al Role of hepatitis B core-related antigen in predicting the occurrence and
recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A
systemic review and meta-analysis.
J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16558. PubMedAbstract available
Retraction: Rami Al Batran, Fouad Al-Bayaty, Mahmood Ameen Abdulla, Mazen M Jamil
Al-Obaidi, Maryam Hajrezaei, Pouya Hassandarvish, Mustafa Fouad, Shahram
Golbabapour, Samaneh Talaee. Gastroprotective effects of Corchorus olitorius. J
Gastroenterol He
J Gastroenterol Hepatol. 2024 Apr 26. doi: 10.1111/jgh.16551. PubMed
GRYZIAK M, Kraj L, Stec R The role of tumor-associated macrophages in hepatocellular carcinoma-from bench
to bedside: A review.
J Gastroenterol Hepatol. 2024 Apr 23. doi: 10.1111/jgh.16564. PubMedAbstract available
LOON E, Narvaez-Barbecho C, Ortiz JP, Balderramo D, et al Impact of self-reported ancestry on the epidemiology of hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 Apr 13. doi: 10.1111/jgh.16578. PubMed
LIU Y, Hu Y, Li B, Su R, et al Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547. PubMedAbstract available
OHAMA H, Hiraoka A, Tada T, Kariyama K, et al Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma
due to hepatitis C virus following the development of direct-acting antiviral
agents.
J Gastroenterol Hepatol. 2024 Apr 11. doi: 10.1111/jgh.16553. PubMedAbstract available
CHAN WK, George J Metabolic fatty liver syndromes: where do we stand in 2024?
J Gastroenterol Hepatol. 2024;39:613-614. PubMed
PARENTE A, Milana F, Hajibandeh S, Hajibandeh S, et al Clinical outcomes after transplantation of domino grafts or standard deceased
donor livers: a systematic review and meta-analysis.
J Gastroenterol Hepatol. 2024;39:620-629. PubMedAbstract available
March 2024
WANG X, Liu H, Wang Y, Wang P, et al Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate
cells through the PI3K/Akt/mTOR pathway.
J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538. PubMedAbstract available
SUZUKI K, Yasui Y, Tsuchiya K, Matsumoto H, et al Impact of immune-related adverse events in patients with hepatocellular carcinoma
treated with atezolizumab plus bevacizumab.
J Gastroenterol Hepatol. 2024 Mar 17. doi: 10.1111/jgh.16532. PubMedAbstract available
BALE G, Kulkarni AV, Padaki NR, Menon PB, et al Comparing rare variants versus common in the pathogenesis of nonalcoholic fatty
liver disease: a whole exome sequencing approach.
J Gastroenterol Hepatol. 2024;39:587-595. PubMedAbstract available
February 2024
SOGABE M, Okahisa T, Kagawa M, Sei M, et al Association of metabolic dysfunction-associated steatotic liver disease with
erosive esophagitis development: a longitudinal observational study.
J Gastroenterol Hepatol. 2024 Feb 29. doi: 10.1111/jgh.16530. PubMedAbstract available
Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of
hepatic nodules in patients with alcoholic liver cirrhosis".
J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529. PubMed
TADA T, Kumada T, Hiraoka A, Kariyama K, et al mADRES predicts hepatocellular carcinoma development in patients with hepatitis C
virus who achieved sustained virological response.
J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16512. PubMedAbstract available
WANG J, Zhang Y, Ma Y, Zhao S, et al TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443. PubMedAbstract available
BATT NM, Rodrigues B, Bloom S, Sawhney R, et al Metabolic-associated fatty liver disease and hepatocellular carcinoma: a
prospective study of characteristics and response to therapy.
J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. PubMedAbstract available
HAHN JW, Lee H, Shin M, Seong MW, et al Diagnostic algorithm for neonatal intrahepatic cholestasis integrating
single-gene testing and next-generation sequencing in East Asia.
J Gastroenterol Hepatol. 2024 Feb 7. doi: 10.1111/jgh.16505. PubMedAbstract available
JI PX, Chen YX, Ni XX, Miao Q, et al Effect of triggering receptor expressed on myeloid cells 2-associated alterations
on lipid metabolism in macrophages in the development of non-alcoholic fatty
liver disease.
J Gastroenterol Hepatol. 2024;39:369-380. PubMedAbstract available
January 2024
TOYODA H, Tada T, Uojima H, Nozaki A, et al Comparison of six hepatocellular carcinoma prediction models in Japanese patients
after sustained virologic response undergoing rigorous surveillance for
hepatocellular carcinoma.
J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494. PubMedAbstract available
AMJAD W, Jiang Z, Lai M Statin use in cirrhosis and its association with incidence of portal vein
thrombosis.
J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495. PubMedAbstract available
DIAO L, Wang C, You R, Leng B, et al Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1
inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
J Gastroenterol Hepatol. 2024 Jan 19. doi: 10.1111/jgh.16463. PubMedAbstract available
ZHU J, Xia Y, Liu X, Zhang C, et al Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis:
A systematic review and meta-analysis.
J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489. PubMedAbstract available
NIE MT, Wang PQ, Shi PM, Hong XL, et al Rifaximin treatment shapes a unique metagenome-metabolism network in patients
with decompensated cirrhosis.
J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484. PubMedAbstract available
SOGABE M, Okahisa T, Kagawa M, Sei M, et al Association of metabolic dysfunction-associated fatty liver disease with
gallstone development: A longitudinal study.
J Gastroenterol Hepatol. 2024 Jan 11. doi: 10.1111/jgh.16483. PubMedAbstract available
December 2023
GOPAL P, Banerjee D, Karad A, Dandi K, et al Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with
cirrhosis of liver.
J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456. PubMed
CHO SH, Song TJ, Oh D, Park DH, et al Endoscopic ultrasound-guided hepaticoduodenostomy versus percutaneous drainage
for right intrahepatic duct dilatation in malignant hilar obstruction.
J Gastroenterol Hepatol. 2023 Dec 18. doi: 10.1111/jgh.16442. PubMedAbstract available
TOSHIDA K, Itoh S, Yoshiya S, Nagao Y, et al Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab
therapy in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol. 2023 Dec 12. doi: 10.1111/jgh.16441. PubMedAbstract available
HUANG X, Zhou LZ, Feng WJ, Liu YQ, et al Circ ubiquitin-like-containing plant homeodomain and RING finger domains protein
1 increases the stability of G9a and ubiquitin-like-containing plant homeodomain
and RING finger domains protein 1 messenger RNA through recruiting eukaryotic
translation
J Gastroenterol Hepatol. 2023 Dec 7. doi: 10.1111/jgh.16408. PubMedAbstract available
YANG Y, Liu S, Li H, Liu Y, et al The protective effect of Nostoc commune Vauch. polysaccharide on alcohol-induced
acute alcoholic liver disease and gut microbiota disturbance in mice.
J Gastroenterol Hepatol. 2023;38:2185-2194. PubMedAbstract available
TONG C, Halengbieke A, Ni X, Han Y, et al Bidirectional relationship between nonalcoholic fatty liver disease and serum
creatinine-to-body weight ratio as a proxy for skeletal muscle mass index.
J Gastroenterol Hepatol. 2023;38:2061-2069. PubMedAbstract available
NARANG M, Shah D, Narang S, Gupta N, et al Ultrasound-guided aspiration in addition to antibiotics for treatment of liver
abscess in children: A randomized controlled trial.
J Gastroenterol Hepatol. 2023;38:2070-2075. PubMedAbstract available
November 2023
SHI L, Feng G, Yang X, Zhang Y, et al Potential of PAQosome as a therapeutic target for hepatic fibrosis.
J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427. PubMedAbstract available
DU S, Cao K, Yan Y, Wang Y, et al Developments and current status of cell-free DNA in the early detection and
management of hepatocellular carcinoma.
J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16416. PubMedAbstract available
ALLAIRE M, Thabut D The applicability of Baveno criteria in the setting of hepatocellular carcinoma
remains a controversy.
J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415. PubMed
FAROOQ U, Tarar ZI, El Alayli A, Kamal F, et al Analyzing the utility of renal replacement therapy to manage hepatorenal syndrome
in alcoholic hepatitis without liver transplantation: a nationwide analysis.
J Gastroenterol Hepatol. 2023 Nov 12. doi: 10.1111/jgh.16388. PubMedAbstract available
SUN J Navigating the complex landscape of non-alcoholic fatty liver disease: From
genomic associate to the AMPK/mTOR pathways.
J Gastroenterol Hepatol. 2023;38:1863-1864. PubMed
TIAN Y, Wang B Unraveling the pathogenesis of non-alcoholic fatty liver diseases through
genome-wide association studies.
J Gastroenterol Hepatol. 2023;38:1877-1885. PubMedAbstract available
WANG Y, Huang Y, Zheng T, Sun C, et al Gastrointestinal hospitalization during COVID-19 pandemic in the United States:
Analysis of a nationwide inpatient sample.
J Gastroenterol Hepatol. 2023;38:1971-1979. PubMedAbstract available
TAKAHASHI A, Takahata Y, Kokubun M, Anzai Y, et al Association between equol and non-alcoholic fatty liver disease in Japanese women
in their 50s and 60s.
J Gastroenterol Hepatol. 2023;38:1958-1962. PubMedAbstract available
MARCONDES-DE-CASTRO IA, Reis-Barbosa PH, Marinho TS, Aguila MB, et al AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver
disease and its progression.
J Gastroenterol Hepatol. 2023;38:1868-1876. PubMedAbstract available
October 2023
QUAN Y, Shou D, Yang S, Cheng J, et al Mdivi1 ameliorates mitochondrial dysfunction in non-alcoholic steatohepatitis by
inhibiting JNK/MFF signaling.
J Gastroenterol Hepatol. 2023 Oct 15. doi: 10.1111/jgh.16372. PubMedAbstract available
OH JH, Saeed WK, Kim HY, Lee SM, et al Hepatic stellate cells activate and avoid death under necroptosis stimuli:
Hepatic fibrosis during necroptosis.
J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368. PubMedAbstract available
GIRI S, Singh A, Kolhe K, Kale A, et al Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378. PubMed
SHOU D, Luo Q, Tang W, Cao C, et al Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation
attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut
microbiota.
J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359. PubMedAbstract available
ITO T, Morooka H, Takahashi H, Fujii H, et al Identification of clinical phenotypes associated with poor prognosis in patients
with nonalcoholic fatty liver disease via unsupervised machine learning.
J Gastroenterol Hepatol. 2023;38:1832-1839. PubMedAbstract available
VAZ K, Kemp W, Majeed A, Lubel J, et al Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years
in conjunction with increased prevalence of obesity and reduction in healthy
lifestyle.
J Gastroenterol Hepatol. 2023;38:1823-1831. PubMedAbstract available
RONG L, Ch'ng D, Jia P, Tsoi KKF, et al Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver
disease: A systematic review and meta-analysis.
J Gastroenterol Hepatol. 2023;38:1682-1694. PubMedAbstract available
TAKAHASHI Y, Seko Y, Yamaguchi K, Takeuchi K, et al Gamma-glutamyl transferase predicts pemafibrate treatment response in
non-alcoholic fatty liver disease.
J Gastroenterol Hepatol. 2023;38:1743-1749. PubMedAbstract available
September 2023
KANG SH, Kim MY, Han SK, Baik SK, et al Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of
decompensated cirrhosis.
J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327. PubMedAbstract available
HIRATA K, Yamamoto Y, Hatanaka K, Kinoshita K, et al Hepatobiliary and pancreatic: Tiny pigmented intra-hepatic ducts stones as the
cause of jaundice and liver failure.
J Gastroenterol Hepatol. 2023 Sep 8. doi: 10.1111/jgh.16350. PubMed
MURAKAMI S, Uchida T, Imamura M, Suehiro Y, et al Correlation between serum pro-inflammatory cytokine levels and the prognosis of
the patients with acute liver failure.
J Gastroenterol Hepatol. 2023;38:1637-1646. PubMedAbstract available
HAN E, Chun HS, Lee YH, Lee JS, et al MAFLD might be better in identifying subjects with sarcopenia or cardiovascular
risk than NAFLD: A nationwide study.
J Gastroenterol Hepatol. 2023;38:1598-1609. PubMedAbstract available